Figures last updated 21 Oct 2026, 11:00 PM IST · How we work · Report an error
What the company does and where it sits in its industry
Sahajanand Medical Technologies develops, manufactures, and markets cardiovascular devices globally. The core business is divided into two primary segments: vascular intervention products, such as coronary stents and balloon catheters, and structural heart devices, including transcatheter aortic valves and occluders. The company generates the majority of its revenue from the sale of vascular intervention devices, with the Supraflex Cruz, a biodegradable polymer-based drug-eluting stent, acting as a major contributor to its sales. Products are distributed across India, Europe, and the rest of the world through a combination of direct, hybrid, and distributor-led models, supported by an extensive network of domestic and international distributors. Operations are backed by manufacturing facilities located in Surat, Hyderabad, and Thailand. Additionally, the business relies heavily on dedicated research and development capabilities to continually enhance existing products and introduce new cardiovascular treatments.
Sahajanand Medical Technologies Limited is a research and development-driven medical devices company focused on the development, manufacturing, and commercialization of Class III and Class C/D advanced cardiovascular devices, with an emphasis on Vascular Intervention (VI) and Structural Heart (SH). Its product offerings include coronary stents, PTCA balloon catheters, drug-coated balloons, transcatheter aortic valve implantation (TAVI) systems, and occluders.
The company serves healthcare providers, cardiologists, catheterization laboratories, and hospitals globally, including major healthcare institutions such as Narayana Hrudayalaya Limited. It markets products in 77 countries across India, Europe, and the Rest of the World through a combination of direct sales, hybrid models, and distributor-led channels.
The company earns revenue primarily from the sale of medical devices and accessories, with Vascular Intervention devices (notably its flagship drug-eluting stent Supraflex Cruz) generating the majority of operating revenues, complemented by growing contributions from structural heart implants and traded accessories.
The company's primary products include coronary drug-eluting stents (Supraflex Cruz), PTCA balloon dilatation catheters (Pipit), coronary drug-coated balloons (Sironity), transcatheter aortic valve implantation systems (Hydra TAVI), and congenital heart defect occluders (Cocoon).
The company operates an integrated manufacturing and direct/hybrid/distributor-led distribution model to develop, produce, and sell advanced cardiovascular devices to hospitals and healthcare providers globally.
The company has a leading market share of nearly 25.00% in the drug-eluting stents market in India by sales volume in Fiscal 2026, and is among the top five companies by DES sales volume in Germany, Spain, Poland, and Brazil.
Who controls the company, and how much of it they hold
BHARGAV DHIRAJLAL KOTADIA, DHIRAJLAL VALLABHBHAI KOTADIA, PRIYANKA DHIRAJLAL COHEN, SHREE HARI TRUST
Points to weigh, drawn from the offer document and the figures on the other tabs
The company offers a comprehensive portfolio of advanced Class III and Class C/D cardiovascular implants backed by clinical evidence and regulatory accreditations.
Operates two dedicated R&D facilities in India and Thailand with 119 granted patents globally and an active pipeline of advanced device innovations.
Holds a leading volume market share of nearly 25.00% in drug-eluting stents in India and ranks among the top five by DES sales volume in Germany, Spain, Poland, and Brazil.
Markets products across 77 countries using tailored direct, hybrid, and distributor-led strategies, with strong relationships among key opinion leaders and hospital networks.
Operates three manufacturing facilities in Surat, Hyderabad, and Nonthaburi (Thailand) accredited by global regulators including CE, ANVISA, and CDSCO, enabling cost-effective production.
The company's products are subject to stringent regulations across multiple jurisdictions, and any adverse action, delays in approvals, or failure to transition to new frameworks like EU MDR could adversely impact operations.
A majority of revenue is derived from Vascular Intervention devices, with flagship stent Supraflex Cruz accounting for 37.17% of total revenue from operations in Fiscal 2026.
The top 10 suppliers accounted for 59.15% of purchases in Fiscal 2026, and the company relies on single or limited sources for critical components such as cobalt chromium tubes and polymers.
With 73.87% of revenue from operations in Fiscal 2026 generated outside India, the company faces significant currency translation and transaction exposure across USD, EUR, and other currencies.
Because implants such as stents and heart valves are high-risk life-sustaining medical devices, any alleged malfunction, defect, or product recall could expose the company to substantial liability claims and reputational damage.